71 related articles for article (PubMed ID: 22266895)
1. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial.
Robinson P; Schechter MS; Sly PD; Winfield K; Smith J; Brennan S; Shinkai M; Henke MO; Rubin BK
Pediatr Pulmonol; 2012 Jun; 47(6):551-7. PubMed ID: 22266895
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis.
Hordvik NL; Sammut PH; Judy CG; Colombo JL
Pediatr Pulmonol; 2002 Oct; 34(4):287-96. PubMed ID: 12205570
[TBL] [Abstract][Full Text] [Related]
3. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.
Pirzada OM; McGaw J; Taylor CJ; Everard ML
J Cyst Fibros; 2003 Jun; 2(2):69-71. PubMed ID: 15463852
[TBL] [Abstract][Full Text] [Related]
4. Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium.
Barker PM; Gillie DJ; Schechter MS; Rubin BK
Am J Respir Crit Care Med; 2005 Apr; 171(8):868-71. PubMed ID: 15657462
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis.
Schnabel D; Grasemann C; Staab D; Wollmann H; Ratjen F;
Pediatrics; 2007 Jun; 119(6):e1230-8. PubMed ID: 17545356
[TBL] [Abstract][Full Text] [Related]
6. Long-term clarithromycin in cystic fibrosis: effects on inflammatory markers in BAL and clinical status.
Doğru D; Dalgiç F; Kiper N; Ozçelik U; Yalçin E; Aslan AT; Gürcan N; Saricaoğlu F; Gür D; Karayazgan Y; Firat P
Turk J Pediatr; 2009; 51(5):416-23. PubMed ID: 20112595
[TBL] [Abstract][Full Text] [Related]
7. Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis.
Stelmach I; Korzeniewska A; Stelmach W; Majak P; Grzelewski T; Jerzynska J
Ann Allergy Asthma Immunol; 2005 Oct; 95(4):372-80. PubMed ID: 16279568
[TBL] [Abstract][Full Text] [Related]
8. Daily versus weekly azithromycin in cystic fibrosis patients.
McCormack J; Bell S; Senini S; Walmsley K; Patel K; Wainwright C; Serisier D; Harris M; Bowler S
Eur Respir J; 2007 Sep; 30(3):487-95. PubMed ID: 17537764
[TBL] [Abstract][Full Text] [Related]
9. Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial.
Suri R; Metcalfe C; Wallis C; Bush A
Respir Med; 2007 Feb; 101(2):254-60. PubMed ID: 16806875
[TBL] [Abstract][Full Text] [Related]
10. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease.
Pukhalsky AL; Shmarina GV; Kapranov NI; Kokarovtseva SN; Pukhalskaya D; Kashirskaja NJ
Mediators Inflamm; 2004 Apr; 13(2):111-7. PubMed ID: 15203552
[TBL] [Abstract][Full Text] [Related]
12. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial.
Kabra SK; Pawaiya R; Lodha R; Kapil A; Kabra M; Vani AS; Agarwal G; Shastri SS
J Cyst Fibros; 2010 Jan; 9(1):17-23. PubMed ID: 19818694
[TBL] [Abstract][Full Text] [Related]
13. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group.
Pons G; Marchand MC; d'Athis P; Sauvage E; Foucard C; Chaumet-Riffaud P; Sautegeau A; Navarro J; Lenoir G
Pediatr Pulmonol; 2000 Jul; 30(1):25-31. PubMed ID: 10862159
[TBL] [Abstract][Full Text] [Related]
14. Exploring the mechanisms of macrolides in cystic fibrosis.
Equi AC; Davies JC; Painter H; Hyde S; Bush A; Geddes DM; Alton EW
Respir Med; 2006 Apr; 100(4):687-97. PubMed ID: 16185859
[TBL] [Abstract][Full Text] [Related]
15. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis.
Eng PA; Morton J; Douglass JA; Riedler J; Wilson J; Robertson CF
Pediatr Pulmonol; 1996 Feb; 21(2):77-83. PubMed ID: 8882210
[TBL] [Abstract][Full Text] [Related]
16. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study.
Bilton D; Robinson P; Cooper P; Gallagher CG; Kolbe J; Fox H; Jaques A; Charlton B;
Eur Respir J; 2011 Nov; 38(5):1071-80. PubMed ID: 21478216
[TBL] [Abstract][Full Text] [Related]
17. Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report.
Sermet-Gaudelus I; Stoven V; Annereau JP; Witko-Sarsat V; Reinert P; Guyot M; Descamps-Latscha B; Lallemand JY; Lenoir G
Mediators Inflamm; 1999; 8(1):13-5. PubMed ID: 10704084
[TBL] [Abstract][Full Text] [Related]
18. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study.
Bruzzese E; Raia V; Spagnuolo MI; Volpicelli M; De Marco G; Maiuri L; Guarino A
Clin Nutr; 2007 Jun; 26(3):322-8. PubMed ID: 17360077
[TBL] [Abstract][Full Text] [Related]
19. Dornase alfa in early cystic fibrosis lung disease.
Robinson PJ
Pediatr Pulmonol; 2002 Sep; 34(3):237-41. PubMed ID: 12203856
[TBL] [Abstract][Full Text] [Related]
20. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
Suri R; Metcalfe C; Wallis C; Bush A
Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
